全文获取类型
收费全文 | 501篇 |
免费 | 35篇 |
专业分类
儿科学 | 28篇 |
妇产科学 | 6篇 |
基础医学 | 50篇 |
口腔科学 | 15篇 |
临床医学 | 65篇 |
内科学 | 93篇 |
皮肤病学 | 14篇 |
神经病学 | 25篇 |
特种医学 | 133篇 |
外科学 | 35篇 |
综合类 | 13篇 |
预防医学 | 18篇 |
眼科学 | 1篇 |
药学 | 18篇 |
肿瘤学 | 22篇 |
出版年
2023年 | 1篇 |
2022年 | 5篇 |
2021年 | 8篇 |
2020年 | 1篇 |
2019年 | 4篇 |
2018年 | 10篇 |
2017年 | 5篇 |
2016年 | 7篇 |
2015年 | 13篇 |
2014年 | 9篇 |
2013年 | 27篇 |
2012年 | 8篇 |
2011年 | 5篇 |
2010年 | 23篇 |
2009年 | 29篇 |
2008年 | 7篇 |
2007年 | 7篇 |
2006年 | 7篇 |
2005年 | 6篇 |
2004年 | 9篇 |
2003年 | 5篇 |
2002年 | 5篇 |
2001年 | 9篇 |
2000年 | 6篇 |
1999年 | 9篇 |
1998年 | 28篇 |
1997年 | 30篇 |
1996年 | 33篇 |
1995年 | 25篇 |
1994年 | 25篇 |
1993年 | 21篇 |
1992年 | 3篇 |
1991年 | 7篇 |
1990年 | 3篇 |
1989年 | 17篇 |
1988年 | 12篇 |
1987年 | 12篇 |
1986年 | 9篇 |
1985年 | 9篇 |
1984年 | 6篇 |
1983年 | 6篇 |
1982年 | 8篇 |
1981年 | 9篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1978年 | 7篇 |
1977年 | 13篇 |
1976年 | 8篇 |
1975年 | 10篇 |
1968年 | 2篇 |
排序方式: 共有536条查询结果,搜索用时 15 毫秒
21.
Fc gamma receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody 总被引:1,自引:1,他引:1
Vervoordeldonk SF; Merle PA; van Leeuwen EF; van der Schoot CE; von dem Borne AE; Slaper-Cortenbach IC 《Blood》1994,83(6):1632-1639
Antigenic modulation is one of many factors determining the effectiveness of monoclonal antibody (MoAb)-mediated therapy. To select the isotype of a CD19 MoAb most suitable for radioimmunotherapy of patients with B-cell malignancies, we studied the influence of MoAb isotype on modulation, after binding of the MoAb to different cell-line cells. The CD19-IgG1 MoAb was found to induce modulation of CD19 antigens on Daudi cell line cells more rapidly than did its IgG2a switch variant. We provide evidence that this difference in modulation rate is caused by the expression of Fc gamma receptor II (Fc gamma RII) on these cells. Experiments aimed at elucidating the mechanism of Fc gamma RII involvement in modulation induction by CD19-IgG1 showed that Fc gamma RII did not comodulate with CD19 MoAbs. However, cocrosslinking of CD19 and Fc gamma RII with CD19-IgG1 MoAb resulted in enhanced calcium mobilization in Daudi cells. This increased signal induction accompanies the enhanced capping and subsequent modulation of CD19 antigens. Because Fc gamma RII is expressed in varying densities on malignant B cells in all differentiation stages, our results have implications for the MoAb isotype most suitable for use in MoAb-based therapy of patients with B-cell malignancies. 相似文献
22.
Histamine reduces boron neutron capture therapy‐induced mucositis in an oral precancer model
下载免费PDF全文
![点击此处可从《Oral diseases》网站下载免费的PDF全文](/ch/ext_images/free.gif)
23.
Anal cancer is one of the most common non‐AIDS‐defining malignancies in the era of combination antiretroviral therapy. Its precursor lesion, anal intraepithelial neoplasia (AIN), is highly prevalent in HIV‐infected populations. More than 90% of anal squamous cell cancers are attributable to human papillomavirus (HPV). While the biology of HPV‐related intraepithelial neoplasia is consistent across lower anogenital sites, the natural history of AIN is not well established and cannot be assumed to be identical to that of cervical intraepithelial neoplasia. Screening strategies to prevent anal cancer should be developed based on robust natural history data in HIV‐infected and uninfected populations. Likewise, treatments need to be tested in randomized clinical trials, and reserved for those at significant risk of progression to cancer. This review covers the epidemiology, pathogenesis and immunology of HPV infection, AIN and anal cancer, and summarizes the current diagnosis, screening and treatment strategies in HIV‐infected adults. 相似文献
24.
25.
Data have been collected from 47 centers in Europe and North America on the treatment with porcine factor VIII concentrate of 74 acute bleeding episodes in 65 patients with acquired hemophilia. The median initial anti-human factor VIII auto-antibody inhibitor level was 38 Bethesda unit (BU)/mL (range 1.2 to 1,024) whereas that against porcine was 1 BU/mL (range 0 to 15). The mean initial dose of porcine factor VIII infused was 84 IU/kg, which increased the plasma factor VIII:C activity by 0.85 IU/mL. Therapy was continued for a mean of 8.5 days during which time the average number of infusions was 11. Objective clinical responses were rated as good or excellent in 78% of recipients. Side effects were uncommon; only one patient experienced a severe anaphylactic reaction necessitating the discontinuation of porcine FVIII therapy. After therapy, no increase in the median level of anti- human FVIII or anti-porcine antibody was noted in the group as a whole, although 13 patients showed individual increases in either anti-human or anti-porcine antibody levels or both of more than 10 BU/mL. Of the 7 patients who subsequently rebled, 5 were successfully re-treated and 2 did not respond to further porcine factor VIII treatment. Porcine factor VIII is safe and clinically effective treatment for bleeding episodes associated with acquired hemophilia and should be considered as first-line therapy for patients whose acquired anti-factor VIII:C antibody cross-reacts with porcine factor VIII:C at low levels. 相似文献
26.
H. M. Bramlett W. D. Dietrich A. Marcillo L. J. Mawhinney O. Furones-Alonso A. Bregy Y. Peng Y. Wu J. Pan J. Wang X. E. Guo W. A. Bauman C. Cardozo W. Qin 《Osteoporosis international》2014,25(9):2209-2219
Summary
Spinal cord injury (SCI) causes rapid and marked bone loss. The present study demonstrates that low-intensity vibration (LIV) improves selected biomarkers of bone turnover and gene expression and reduces osteoclastogenesis, suggesting that LIV may be expected to benefit to bone mass, resorption, and formation after SCI.Introduction
Sublesional bone is rapidly and extensively lost following spinal cord injury (SCI). Low-intensity vibration (LIV) has been suggested to reduce loss of bone in children with disabilities and osteoporotic women, but its efficacy in SCI-related bone loss has not been tested. The purpose of this study was to characterize effects of LIV on bone and bone cells in an animal model of SCI.Methods
The effects of LIV initiated 28 days after SCI and provided for 15 min twice daily 5 days each week for 35 days were examined in female rats with moderate severity contusion injury of the mid-thoracic spinal cord.Results
Bone mineral density (BMD) of the distal femur and proximal tibia declined by 5 % and was not altered by LIV. Serum osteocalcin was reduced after SCI by 20 % and was increased by LIV to a level similar to that of control animals. The osteoclastogenic potential of bone marrow precursors was increased after SCI by twofold and associated with 30 % elevation in serum CTX. LIV reduced the osteoclastogenic potential of marrow precursors by 70 % but did not alter serum CTX. LIV completely reversed the twofold elevation in messenger RNA (mRNA) levels for SOST and the 40 % reduction in Runx2 mRNA in bone marrow stromal cells resulting from SCI.Conclusion
The findings demonstrate an ability of LIV to improve selected biomarkers of bone turnover and gene expression and to reduce osteoclastogenesis. The study indicates a possibility that LIV initiated earlier after SCI and/or continued for a longer duration would increase bone mass. 相似文献27.
28.
29.
30.